HIV Stigma is Associated with Patient-Reported Outcomes and Quality of Life Among Black Sexual Minority Men Living With HIV – Slides

Oral Presentation at the CHIPTS HIV Next Generation Conference featuring Chenglin Hong held on January 2022. The presentation examines the effect of HIV stigma, which might be pronounced among Black sexual minority men living with HIV due to the Intersectionality and multiple minority stressors. Findings underscore the critical associations between HIV stigma and patient-reported mental health outcomes and quality of life.

Using PrEP is Being Part of a Larger Movement: Additional Individual and Community Level Benefits of PrEP Use Among Latino Gay and Bisexual Men – Slides

Oral Presentation at the CHIPTS HIV Next Generation Conference featuring Omar Nieto and Ronald Brooks held on January 2022. The presentation examines the additional benefits of using PrEP specifically among Latino GBM PrEP users. Semi-structured interviews were conducted with participants to identify feelings and emotions experienced, plus any additional benefits gained from using PrEP.

Correlates of Sexual Contact, COVID Testing, and Comfort Attending Sexual Venues During the COVID-19 Pandemic in a Global Sample of Gay, Bisexual, and Other Men Who Have Sex with Men – Slides

Oral Presentation at the CHIPTS HIV Next Generation Conference featuring Juan C. Jauregui held on January 2022. The presentation describes how gay social and sexual venues are important targets for HIV prevention engagement and how GBMSM continued to remain connected through gay geosocial networking apps throughout the pandemic. The presentation examines the impact of COVID-19 on GBMSM’s social and sexual venue attendance.

The Trials and Tribulations of Using Telehealth for Building Brothers Up (2BU) – Slides

Oral presentation by Kimberly A. Kisler at the Delivery of Telehealth in Clinical Care and Research Interventions: Challenges, Barriers, Success, and Future Considerations conference on June 2021. The presentation described the challenges, barriers, successes, & future considerations of the BUILDING BROTHERS UP (2BU) project which aims to reduce HIV transmission and acquisition and the risks that can result from substance use among BMSM living with HIV, ages 18-65 years.

Long-acting injectable CAB vs. daily oral TDF/FTC for PrEP among MSM and TGW – Slides

Oral presentation by Raphael J. Landovitz at the HPTN Annual Meeting in May 2021. The presentation provided a rapid overview of the HPTN 083 study, the study describes the CAB as the first long-acting injectable agent to demonstrate robust HIV prevention efficacy. The result of this study shows that The PrEP regimen containing CAB-LA was superior to a daily oral regimen of TDF/FTC.

Long-Acting Injectable Cabotegravir for HIV PrEP – Q&A Session

Question and answer supplemental document provided by Raphael J. Landovitz for the UCLA HIV Grand Rounds in May 2021. The presentation discussed the HIV Prevention Trials Network (HPTN) 083, a randomized, active-controlled, double-blind clinical trial that began in December 2016. The study has compared the safety and efficacy of two drugs for use as PrEP among a population at increased risk of HIV infection that included MSM ages 18+.

Long-Acting Injectable Cabotegravir for HIV PrEP – Slides

Oral presentation by Raphael J. Landovitz at the UCLA HIV Grand Rounds in May 2021. The presentation discussed the HIV Prevention Trials Network (HPTN) 083, a randomized, active-controlled, double-blind clinical trial that began in December 2016. The study has compared the safety and efficacy of two drugs for use as PrEP among a population at increased risk of HIV infection that included MSM ages 18+.

Long-Acting Injectable Cabotegravir for HIV PrEP – Flyer

Flyer for the upcoming UCLA HIV Grand Rounds in May 2021 featuring Raphael Landovtz. The presentation will discuss the HIV Prevention Trials Network (HPTN) 083, a randomized, active-controlled, double-blind clinical trial that began in December 2016. The study has compared the safety and efficacy of two drugs for use as PrEP among a population at increased risk of HIV infection that included MSM ages 18+.